Patent application number | Description | Published |
20090136446 | INDUCTION OF REGULATORY T CELL-RESISTANT HELPER CD4+ T CELLS - The invention relates to stimulation of immune responses against antigen(s) and overcoming regulatory T cell suppression of such immune responses against antigen(s). | 05-28-2009 |
20090324566 | T-Cell Receptor and Nucliec Acid Encoding the Receptor - A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of constituting an HLA-A24-restricted, MAGE-A4 | 12-31-2009 |
20100247579 | THERAPEUTIC AGENT FOR CANCER - The present invention relates to a method for treatment of cancer, which comprises the following steps (A) and (B): (A) applying a treatment which induces the reduction in lymphocytes to a patient; and (B), subsequent to step (A), administering lymphocytes to the patient promptly. The present invention also relates to a cancer therapeutic agent and a cancer treatment kit for use in the method. When the method is used as an immunoreconstructive therapy, the decrease in immunologic competence which may be caused by the reduction in lymphocytes can be avoided and, therefore, the risk of the occurrence of an infectious disease can be decreased. | 09-30-2010 |
20100273213 | METHOD FOR EXPRESSION OF SPECIFIC GENE - Disclosed is a cell which can express a non-natural oligomeric protein, which has, introduced therein, a gene encoding an exogenous polypeptide corresponding to at least one endogenous polypeptide constituting a natural oligomeric protein, and in which the expression of the endogenous polypeptide is inhibited. | 10-28-2010 |
20140242701 | CHIMERIC ANTIGEN RECEPTOR - Provided are a chimeric antigen receptor comprising an extracellular domain capable of binding to an antigen, a transmembrane domain and at least one intracellular domain, the chimeric antigen receptor being characterized in that an intracellular domain of a glucocorticoid-induced tumor necrosis factor receptor (GITR) is contained as the intracellular domain; a nucleic acid encoding the chimeric antigen receptor; a cell expressing the chimeric antigen receptor; and a method for producing the cell. | 08-28-2014 |
Patent application number | Description | Published |
20090068209 | Cytotoxic Lymphocyte - The present invention relates to a T lymphocyte having an activity to induce a T lymphocyte recognizing an antigen and a technique to use the T lymphocyte. | 03-12-2009 |
20090246213 | VACCINE COMPRISING A POLYNUCLEOTIDE ENCODING AN ANTIGEN RECOGNIZED BY A CD4+ HELPER T-CELL AND A POLYNUCLEOTIDE ENCODING A TUMOR SPECIFIC OR ASSOCIATED ANTIGEN RECOGNIZED BY A CD8+ CTL - The present invention relates to a DNA vaccine for developing tumor-specific immunity. Specifically, the invention relates to a DNA vaccine comprising antigens recognized by CD4 | 10-01-2009 |
20110250230 | CELL CAPABLE OF EXPRESSING EXOGENOUS GITR LIGAND - Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject. | 10-13-2011 |
20110256114 | T-CELL RECEPTOR AND NUCLEIC ACID ENCODING THE RECEPTOR - A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of constituting an HLA-A24-restricted, MAGE-A4 | 10-20-2011 |
20110318839 | METHOD FOR ENHANCING A FUNCTION OF A T CELL - Disclosed is a method for enhancing the function of a T cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (PD-L1) and/or programmed death-1 ligand 2 (PD-L2) in the T cell. Also disclosed is a function-enhanced T cell which is produced by the function enhancement method. Further disclosed is a therapeutic agent comprising the function-enhanced T cell. The T cell can enhance an immune response to cancer, and is useful in an immunotherapy effective for cancer and the treatment or prevention of infectious diseases and autoimmune diseases. | 12-29-2011 |
20120238012 | CYTOTOXIC T LYMPHOCYTE - The present invention relates to a T lymphocyte having an activity to induce a T lymphocyte recognizing an antigen and a technique to use the T lymphocyte. | 09-20-2012 |
20130115199 | T-CELL RECEPTOR AND NUCLEIC ACID ENCODING THE RECEPTOR - A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of constituting an HLA-A24-restricted, MAGE-A4 | 05-09-2013 |
20140120124 | CELL CAPABLE OF EXPRESSING EXOGENOUS GITR LIGAND - Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject. | 05-01-2014 |
20140322344 | VACCINE PREPARATION FOR CANCER TREATMENT - A vaccine preparation for treating cancer includes a complex of a hydrophobized polysaccharide and at least one synthetic long peptide derived from a tumor-specific antigenic protein and/or a pathogen-derived antigenic protein. The at least one synthetic long peptide contains at least one CD8+ cytotoxic T-cell recognition epitope and at least one CD4+ helper T-cell recognition epitope. The complex is simultaneously administered to the patient with at least one immunopotentiating agent. | 10-30-2014 |